BillionToOne Adds Genmab CFO Anthony Pagano to Board, Names Him Audit Chair

New updates have been reported about BillionToOne (PC:BILLI)

BillionToOne, Inc. has strengthened its governance and financial oversight by appointing Anthony Pagano to its Board of Directors and naming him Chair of the Audit Committee, effective January 1, 2026. Pagano currently serves as Chief Financial Officer and Executive Vice President of Genmab and brings extensive public-company finance, capital markets, and audit experience to BillionToOne as it scales its precision diagnostics platform. His track record at Genmab, where revenue expanded from roughly $100 million to more than $3 billion during his tenure, signals a focus on building financial discipline, investor credibility, and readiness for sustained growth in BillionToOne’s transition as a listed company.

BillionToOne’s CEO and co-founder, Dr. Oguzhan Atay, emphasized that Pagano’s experience in guiding high-growth life sciences enterprises is expected to support the company’s ambition to build a category-defining molecular diagnostics franchise. As Audit Committee Chair, Pagano will play a central role in overseeing financial reporting, internal controls, and risk management at a time when the company is advancing its Quantitative Counting Templates (QCT) molecular counting platform, which enables single-molecule level DNA quantification. Pagano, a CPA with an MBA from NYU Stern and earlier roles at NovaDel Pharma and KPMG, noted that he views BillionToOne’s technology and team as well-positioned for its next growth phase. The company cautioned that expectations about future growth and technology advancement are forward-looking and subject to regulatory, operational, and market risks disclosed in its SEC filings, underscoring the importance of the enhanced audit and governance capabilities Pagano is expected to provide.